Interpace, Affirma, and Thyroseq Performance Characteristics in 341 Bethesda Category III/IV Thyroid Nodules

被引：0
|
作者：
Connelly, C. F. [1 ]
Cimic, A. [2 ]
Baskota, S. [2 ]
机构：
[1] Columbia Univ, Irving Med Ctr, New York Presbyterian, New York, NY USA
[2] Columbia Univ, Irving Med Ctr, New York, NY USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2023年 / 160卷
关键词：
D O I：
10.1093/ajcp/aqad150.051
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
aqad150.05
引用
收藏
页码：S23 / S24
页数：2
相关论文
共 50 条
  • [31] Interobserver Variability and Correlation of Nuclear and Architectural Features in Thyroid FNAs Diagnosed as Bethesda III or IV with ThyroSeq Results
    Bobb, Bryce
    Jenkins, Taylor
    Sayeed, Sadia
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [32] Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules
    Jin, Xiaobing
    Lew, Madelyn
    Pantanowitz, Liron
    Smola, Brian
    Jing, Xin
    CANCER CYTOPATHOLOGY, 2022, 130 (11) : 891 - 898
  • [33] Performance of Afirma Genomic Sequencing Classifier and Histopathological Outcome Are Associated with Subtype of Atypia in Bethesda Category III Thyroid Nodules
    Jin, Xiaobing
    Lew, Madelyn
    Smola, Brian
    Pantanowitz, Liron
    Jing, Xin
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 263 - 264
  • [34] Performance of Afirma Genomic Sequencing Classifier and Histopathological Outcome Are Associated with Subtype of Atypia in Bethesda Category III Thyroid Nodules
    Jin, Xiaobing
    Lew, Madelyn
    Smola, Brian
    Pantanowitz, Liron
    Jing, Xin
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 263 - 264
  • [35] Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS): Is There a Correct Answer?
    Heller, Keith S.
    THYROID, 2014, 24 (05) : 787 - 788
  • [36] Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology
    Raghunathan, Rajam
    Longstaff, Xochitl R.
    Hughes, Elena G.
    Li, Shanpeng J.
    Sant, Vivek R.
    Tseng, Chi-Hong
    Rao, Jianyu
    Wu, James X.
    Yeh, Michael W.
    Livhits, Masha J.
    SURGERY, 2024, 175 (01) : 221 - 227
  • [37] Approach to Bethesda system category III thyroid nodules according to US-risk stratification
    Kim, Jieun
    Shin, Jung Hee
    Oh, Young Lyun
    Hahn, Soo Yeon
    Park, Ko Woon
    ENDOCRINE JOURNAL, 2022, 69 (01) : 67 - 74
  • [38] Thyroid Nodules Bethesda Category III (CIII-B): Clinical, Ultrasound and Evolution Correlation
    Varela, Gustavo
    Picon, Nicolas
    Susana Sala, Monica
    Arce, Patricia
    Paes de Lima, Andrea
    Tessone, Licina
    Castiglione, T.
    Elsner, Boris
    Arebalo de Cross, Graciela
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [39] Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective
    Zahid, Adnan
    Shafiq, Waqas
    Nasir, Khawaja Shehryar
    Loya, Asif
    Raza, Syed Abbas
    Sohail, Sara
    Azmat, Umal
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2021, 23
  • [40] Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda Category III in an endemic region
    Kasap, Zeliha Aydin
    Kurt, Burcin
    Ozsagir, Elif
    Ercin, Mustafa Emre
    Guner, Ali
    DIAGNOSTIC CYTOPATHOLOGY, 2024, 52 (04) : 200 - 210
12345